Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H31NO4S |
| Molecular Weight | 429.572 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]4([H])[C@@]2([H])CC=C5C[C@H](CC[C@]45C)OS(O)(=O)=O
InChI
InChIKey=LUQSJWRTYLGZJB-VJLLXTKPSA-N
InChI=1S/C24H31NO4S/c1-23-11-9-18(29-30(26,27)28)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22H,6,8-12,14H2,1-2H3,(H,26,27,28)/t18-,19-,21-,22-,23-,24+/m0/s1
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3721 |
0.044 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ZYTIGA Approved UseZYTIGA is a CYP17 inhibitor indicated for use in combination with
prednisone for the treatment of patients with metastatic castration-resistant
prostate cancer who have received prior chemotherapy containing docetaxel. Launch Date2011 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
WZ5U45K71V
Created by
admin on Sat Dec 16 09:30:39 GMT 2023 , Edited by admin on Sat Dec 16 09:30:39 GMT 2023
|
PRIMARY | |||
|
91827106
Created by
admin on Sat Dec 16 09:30:39 GMT 2023 , Edited by admin on Sat Dec 16 09:30:39 GMT 2023
|
PRIMARY |
PARENT (METABOLITE INACTIVE)
SUBSTANCE RECORD
